| 000 | 01727 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250514184758.0 | ||
| 264 | 0 | _c20050906 | |
| 008 | 200509s 0 0 eng d | ||
| 022 | _a1525-4135 | ||
| 024 | 7 |
_a10.1097/00126334-200404010-00007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcCallister, Scott | |
| 245 | 0 | 0 |
_aA 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. _h[electronic resource] |
| 260 |
_bJournal of acquired immune deficiency syndromes (1999) _cApr 2004 |
||
| 300 |
_a376-82 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrones _xadministration & dosage |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 | _aSulfonamides |
| 700 | 1 | _aValdez, Hernan | |
| 700 | 1 | _aCurry, Kevin | |
| 700 | 1 | _aMacGregor, Thomas | |
| 700 | 1 | _aBorin, Marie | |
| 700 | 1 | _aFreimuth, William | |
| 700 | 1 | _aWang, Yenyung | |
| 700 | 1 | _aMayers, Douglas L | |
| 773 | 0 |
_tJournal of acquired immune deficiency syndromes (1999) _gvol. 35 _gno. 4 _gp. 376-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00126334-200404010-00007 _zAvailable from publisher's website |
| 999 |
_c14809498 _d14809498 |
||